WallStSmart

Aurora Cannabis Inc (ACB)vsTeva Pharma Industries Ltd ADR (TEVA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Teva Pharma Industries Ltd ADR generates 4550% more annual revenue ($17.35B vs $373.12M). TEVA leads profitability with a 9.0% profit margin vs -22.5%. TEVA earns a higher WallStSmart Score of 62/100 (C+).

ACB

Avoid

34

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 5.0Quality: 7.0
Piotroski: 5/9Altman Z: -7.92

TEVA

Buy

62

out of 100

Grade: C+

Growth: 6.0Profit: 7.0Value: 7.3Quality: 4.8
Piotroski: 6/9Altman Z: 0.28
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ACB.

TEVAUndervalued (+46.3%)

Margin of Safety

+46.3%

Fair Value

$63.92

Current Price

$35.73

$28.19 discount

UndervaluedFair: $63.92Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ACB2 strengths · Avg: 9.5/10
Price/BookValuation
0.5x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.199/10

Conservative balance sheet, low leverage

TEVA2 strengths · Avg: 9.5/10
EPS GrowthGrowth
72.2%10/10

Earnings expanding 72.2% YoY

Return on EquityProfitability
21.6%9/10

Every $100 of equity generates 22 in profit

Areas to Watch

ACB4 concerns · Avg: 2.5/10
Market CapQuality
$202.80M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
2.3%3/10

Operating margin of 2.3%

Return on EquityProfitability
-15.5%2/10

ROE of -15.5% — below average capital efficiency

EPS GrowthGrowth
-94.7%2/10

Earnings declined 94.7%

TEVA4 concerns · Avg: 3.0/10
P/E RatioValuation
26.9x4/10

Moderate valuation

Revenue GrowthGrowth
2.3%4/10

2.3% revenue growth

Free Cash FlowQuality
$-208.00M2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
0.282/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : ACB

The strongest argument for ACB centers on Price/Book, Debt/Equity.

Bull Case : TEVA

The strongest argument for TEVA centers on EPS Growth, Return on Equity.

Bear Case : ACB

The primary concerns for ACB are Market Cap, Operating Margin, Return on Equity.

Bear Case : TEVA

The primary concerns for TEVA are P/E Ratio, Revenue Growth, Free Cash Flow.

Key Dynamics to Monitor

ACB profiles as a turnaround stock while TEVA is a value play — different risk/reward profiles.

ACB carries more volatility with a beta of 1.33 — expect wider price swings.

ACB is growing revenue faster at 6.8% — sustainability is the question.

ACB generates stronger free cash flow (11M), providing more financial flexibility.

Bottom Line

TEVA scores higher overall (62/100 vs 34/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Aurora Cannabis Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Aurora Cannabis Inc. produces and distributes medical cannabis products globally. The company is headquartered in Edmonton, Canada.

Teva Pharma Industries Ltd ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.

Want to dig deeper into these stocks?